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BACKGROUND: Circulating SN (secretoneurin) concentrations are increased 
in patients with myocardial dysfunction and predict poor outcome. Because 
SN inhibits CaMKIIδ (Ca2+/calmodulin-dependent protein kinase IIδ) activity, we 
hypothesized that upregulation of SN in patients protects against cardiomyocyte 
mechanisms of arrhythmia.
METHODS: Circulating levels of SN and other biomarkers were assessed in patients 
with catecholaminergic polymorphic ventricular tachycardia (CPVT; n=8) and in 
resuscitated patients after ventricular arrhythmia–induced cardiac arrest (n=155). 
In vivo effects of SN were investigated in CPVT mice (RyR2 [ryanodine receptor 
2]-R2474S) using adeno-associated virus-9–induced overexpression. Interactions 
between SN and CaMKIIδ were mapped using pull-down experiments, mutagenesis, 
ELISA, and structural homology modeling. Ex vivo actions were tested in Langendorff 
hearts and effects on Ca2+ homeostasis examined by fluorescence (fluo-4) and patch-
clamp recordings in isolated cardiomyocytes.
RESULTS: SN levels were elevated in patients with CPVT and following ventricular 
arrhythmia–induced cardiac arrest. In contrast to NT-proBNP (N-terminal pro-
B-type natriuretic peptide) and hs-TnT (high-sensitivity troponin T), circulating 
SN levels declined after resuscitation, as the risk of a new arrhythmia waned. 
Myocardial pro-SN expression was also increased in CPVT mice, and further 
adeno-associated virus-9–induced overexpression of SN attenuated arrhythmic 
induction during stress testing with isoproterenol. Mechanistic studies mapped 
SN binding to the substrate binding site in the catalytic region of CaMKIIδ. 
Accordingly, SN attenuated isoproterenol induced autophosphorylation of 
Thr287-CaMKIIδ in Langendorff hearts and inhibited CaMKIIδ-dependent 
RyR phosphorylation. In line with CaMKIIδ and RyR inhibition, SN treatment 
decreased Ca2+ spark frequency and dimensions in cardiomyocytes during 
isoproterenol challenge, and reduced the incidence of Ca2+ waves, delayed 
afterdepolarizations, and spontaneous action potentials. SN treatment also 
lowered the incidence of early afterdepolarizations during isoproterenol; an effect 
paralleled by reduced magnitude of L-type Ca2+ current.
CONCLUSIONS: SN production is upregulated in conditions with cardiomyocyte 
Ca2+ dysregulation and offers compensatory protection against cardiomyocyte 
mechanisms of arrhythmia, which may underlie its putative use as a biomarker in 
at-risk patients.
VISUAL OVERVIEW: A visual overview is available for this article.
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CaMKIIδ (calcium/calmodulin-dependent pro-tein kinase II δ) is an important contributor to arrhythmogenesis in a broad range of cardiac 
pathologies, including heart failure (HF), atrial fibrilla-
tion, ischemia/reperfusion injury, and catecholaminer-
gic polymorphic ventricular tachycardia (CPVT).1 At the 
level of the single cardiac myocyte, CaMKIIδ activation 
is linked to perturbation of Ca2+ homeostasis and the 
generation of spontaneous action potentials. Such ef-
fects are particularly prominent during β-adrenergic 
stimulation, which leads to autophosphorylation of 
CaMKIIδ at Thr287 and sustained kinase activity.2,3 Al-
though the proarrhythmic actions of CaMKIIδ activa-
tion are complex, a central role of CaMKIIδ-dependent 
phosphorylation of RyR2 (ryanodine receptor 2) is well 
established.4 The resulting sensitization of the RyR2 
promotes spontaneous Ca2+ release and the genera-
tion of delayed afterdepolarizations (DADs), as released 
Ca2+ is extruded by the Na+-Ca2+ exchanger. Increased 
CaMKIIδ activity has also been linked to increased risk 
of early afterdepolarizations (EADs) during the down-
stroke of the action potential and resulting extrasys-
toles. Various underlying mechanisms have been pro-
posed, including CaMKIIδ-dependent phosphorylation 
of the L-type Ca2+ channel and a resulting increase in 
channel open probability.5,6 Thus, enhanced CaMKIIδ 
activity is linked to Ca2+-dependent arrhythmogenesis 
by multiple mechanisms.
The established role of CaMKIIδ in arrhythmia has 
stimulated considerable interest in CaMKIIδ inhibitors 
as potential therapeutics. Although such agents have 
been shown to protect against the generation of EADs, 
DADs, and in vivo arrhythmia,1,4 these inhibitors typical-
ly exhibit significant off-target effects or limited uptake 
into cardiomyocytes, which precludes their applicabil-
ity for use in patients.3 We recently reported that the 
peptide SN (secretoneurin) likely serves as an endog-
enous CaMKIIδ inhibitor by an unknown mechanism.7 
Produced by cleavage of the granin protein pro-SN (SgII 
[secretogranin II]),8 we observed that SN is readily taken 
up into cardiomyocytes by endocytosis. We have also 
found increased circulating SN levels in various cohorts 
of patients with myocardial dysfunction, and that SN 
measurements add prognostic information to hs-TnT 
(high-sensitivity troponin T) and NT-proBNP (N-terminal 
pro-B-type natriuretic peptide) measurements.7,9–12 In a 
manner analogous to BNP,13 the biomarker capacity of 
SN may be indicative of its central role in cardiovascular 
disease, including possibly serving as a compensatory 
response to quell the proarrhythmic actions of CaMKIIδ 
in at-risk patients. Accordingly, in this study, we hypoth-
esized that patients prone to Ca2+-dependent arrhyth-
mias would exhibit elevated SN levels and that SN 
would directly inhibit Ca2+-dependent arrhythmias both 
in vivo and in isolated cardiomyocytes.
METHODS
A detailed Methods section is provided in the Data 
Supplement. Requests by researchers to access the data, 
analytical methods, and study materials for the purposes 
of reproducing the results or replicating procedures can be 
made to the corresponding author.
All animal experiments were approved by the Norwegian 
Animal Research Committee and conformed to the Guide 
for the Care and Use of Laboratory Animals published by the 
US National Institutes of Health (National Institutes of Health 
Publication No. 85-23, revised 1996). The clinical studies were 
approved by the Regional Ethics Committees and performed 
according to the Declaration of Helsinki. All subjects or 
next-in-kin provided written informed consent before study 
commencement.
Patients With CPVT, Healthy Control 
Subjects and Patients With Ventricular 
Arrhythmias
Levels of SN and standard biomarkers were assessed in 2 
clinical cohorts. First, we recruited 8 patients with genotype-
verified CPVT from 3 families and 9 age- and sex-matched 
control subjects. Blood sampling of control subjects and 
patients  with CPVT was conducted immediately before 
and after a maximal bicycle exercise stress test. Second, SN 
levels were measured in blood samples from 155 patients 
with ventricular arrhythmia–induced out-of-hospital cardiac 
arrest included in the FINNRESUSCI study, at a range of 
time points after hospitalization (<6, 24, 48, and 96 hours). 
Biomarker levels during the early phase of hospitalization 
were previously reported from this cohort.7
SN Overexpression in CPVT Mice and In 
Vivo Testing of Arrhythmia Inducibility
Microarray analysis of left ventricular tissue was performed 
on female heterozygous RyR2-R2474S CPVT (RyR-RS) 
mice14,15 and their wild-type (WT) littermates (age 8– 12 
WHAT IS KNOWN?
• Circulating SN (secretoneurin) levels are elevated in 
patients with myocardial dysfunction and predict 
poor outcome.
• SN inhibits the activity of CaMKIIδ (Ca2+/calmod-
ulin-dependent protein kinase IIδ), a known con-
tributor to cardiomyocyte pathophysiology.
WHAT THE STUDY ADDS?
• SN levels are increased in patients at risk for 
arrhythmia and may serve as a biomarker for iden-
tifying these individuals.
• Upregulation of SN is compensatory, as direct 
binding to CaMKIIδ inhibits cardiomyocyte mecha-
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weeks). Mice were treated with NaCl or 20 mg/kg iso-
proterenol sulfate for 3 days via an osmotic minipump, 
and myocardial RNA was prepared using TRIzol RNA iso-
lation reagent (Invitrogen) following the manufacturer’s 
instructions. Microarray analysis was performed using the 
Affymetrix GeneChip Mouse Gene 1.0 ST array (Affymetrix).
In vivo antiarrhythmic effects were tested by overexpress-
ing SN in newborn (3–5 days old) male and female RyR2-
R2474S mice14,15 using a single injection of adeno-associated 
virus 9, an approach that leads to robust expression in the 
heart into adulthood.16 When the adeno-associated virus-
9–infected mice reached adulthood, telemetric ECG transmit-
ters were implanted as previously described.15 A stress test 
was performed using an intraperitoneal injection of 20 mg/kg 
isoproterenol, whereas ECG recordings were collected. After 
the stress test, animals were euthanized and ventricular tissue 
was snap-frozen in liquid nitrogen for subsequent validation 
of adeno-associated virus-9–induced expression of SN or con-
trol peptide.
Transfection of Human Embryonic Kidney 
293 Cells, Pull-Down Experiments, 
Structure Modeling and ELISA
Human embryonic kidney 293 cells were cultured as 
described previously17 and transiently transfected with 
various constructs of FLAG-CaMKIIδ. For pull-down experi-
ments, biotinylated synthetic SN peptide was coupled onto 
monoclonal anti–biotin-conjugated beads, incubated with 
the human embryonic kidney 293 lysate and analyzed by 
Western blotting. Atomic coordinates for human CaMKIIδ 
were used to model putative sites of SN binding with 
the substrate-binding domain (S-site). Model validity was 
tested by creating SN mutants and analyzing effects on 
SN-CaMKIIδ binding using an ELISA assay.
Langendorff Preparations and Western 
Blotting Experiments
Mouse hearts were mounted on a Langendorff setup by 
cannulating the aorta and perfused with Hepes Tyrode solu-
tion supplemented with isoproterenol (100 nmol/L) or with 
isoproterenol and SN (2.8 µmol/L). After perfusion, the left 
ventricle was rapidly excised, frozen in liquid nitrogen, and 
stored at −70°C. Protein lysates and Western blotting were 
performed as previously reported.7
Cardiomyocyte Isolation, Ca2+-Dependent 
Fluorescence, and Patch-Clamping 
Experiments
Cells were enzymatically isolated from C57BJ/6 mice by per-
fusing the heart with collagenase type II via a Langendorff 
setup as previously described.7 Ca2+ sparks were recorded in 
resting cardiomyocytes using a confocal microscope in line-
scan mode, with testing of 2 doses of SN (2.8 µmol/L, 2.8 
nmol/L). Whole-cell Ca2+ transients and Ca2+ waves were 
examined by wide-field fluorescence, whereas patch-clamp 
experiments were performed to record action potentials 
and L-type Ca2+ currents (Methods in the Data Supplement).
Statistical Analyses
Statistical tests used are noted in the figure legends accom-
panying each data set. Statistical differences between 
patients with  CPVT and control subjects were examined 
by a Mann-Whitney U test (Figure 1A, Table I in the Data 
Supplement). Correlations between SN levels and other bio-
markers were examined by Spearman correlation (Table II in 
the Data Supplement). In patients resuscitated from ventric-
ular arrhythmias, differences between baseline biomarker 
concentrations and later time points were assessed by the 
Friedman test for repeated measures of nonparametric data 
(Figure  1B). Comparison of patient characteristics accord-
ing to 1-year mortality was examined by a Mann-Whitney 
U test (Table III in the Data Supplement), and correlation 
coefficients were examined by Spearman correlation (Table 
IV in the Data Supplement). Multivariable linear regres-
sion analysis was used to identify variables associated with 
changes in biomarker concentration, including age, sex, 
body mass index, creatinine clearance, established coronary 
artery disease, hypertension, previous HF, diabetes mellitus, 
witnessed cardiac arrest, performed bystander CPR, thera-
peutic hypothermia, Simplified Acute Physiology Score II, 
and Sequential Organ Failure Assessment score (Table V in 
the Data Supplement). In experiments examining WT and 
CPVT mice, statistical significance for microarray data was 
determined by a false discovery rate <0.001 (Figure  2A). 
Polymerase chain reaction analysis of mCherry fusion pro-
tein, the frequency of arrhythmia events, and arrhythmia 
score were tested by 1-way ANOVA on Ranks with Dunn 
test for multiple comparisons (Figure  2C, 2E, and 2F). 
The incidence of ventricular tachycardia was tested with 
a Fisher exact test (Figure  2G). Results from mutagenesis 
studies (Figure 3E) were examined by 1-way ANOVA with 
Bonferroni test for multiple comparisons. In cardiomyocyte 
experiments (Figures 4 and 5, Figures I and II in the Data 
Supplement), statistical differences between groups were 
calculated by Mann-Whitney tests, except for differences 
in the L-type Ca2+ current-voltage relationship, which were 
tested by 2-way ANOVA with Bonferroni test for multi-
ple comparisons. Western blot data were examined with 
Student t test (Figures  3F and 4A, Figure IIB in the Data 
Supplement). A P value of <0.05 was considered statistically 
significant.
RESULTS
SN Levels Are Increased in Subjects With 
CPVT and Patients With Out-of-Hospital 
Cardiac Arrest
Based on our previous observations that SN regulates 
cardiomyocyte Ca2+ homeostasis,7 we hypothesized 
that SN may be specifically linked to Ca2+-dependent 
arrhythmias. To this end, we examined circulating SN 
levels in patients and mice with CPVT, who exhibit 
dysfunctional cardiomyocyte Ca2+-handling during 
β-adrenergic activation. Baseline circulating levels of 
SN were elevated in patients with CPVT compared with 
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Table I in the Data Supplement). In contrast, levels of 
catecholamines, hs-TnT, NT-proBNP, and chromogranins 
were not higher in patients with CPVT compared with 
controls (Figure  1A, Table I in the Data Supplement). 
All of the patients with CPVT, but none of the control 
subjects, were treated with β-blockers (mean dose 
50±32% of recommended target dose). No statistically 
significant linear correlations were observed between 
circulating SN levels and levels of catecholamines, 
established cardiac biomarkers, chromogranins, or 
β-blocker dose (Table II in the Data Supplement), and 
SN levels were not influenced by a short-term bicycle 
exercise stress test (Figure 1A). We also found increased 
myocardial pro-SN mRNA concentrations in CPVT mice 
compared with controls (Figure  2A), which were not 
treated with β-blockers.
We next compared the temporal profile of SN levels 
with the profiles of hs-TnT and NT-proBNP in patients 
that were hospitalized after resuscitation for ventricular 
arrhythmia–induced out-of-hospital cardiac arrest. Cir-
culating SN levels were elevated upon hospital admis-
sion (<6 hours after hospitalization) compared with later 
time points (Figure 1B, Table III in the Data Supplement), 
when the risk of subsequent ventricular arrhythmias and 
mortality are high.18 SN levels then rapidly declined and 
remained low during the subsequent days of follow-
up. In contrast, NT-proBNP levels increased during the 
first days after ventricular arrhythmia, whereas hs-TnT 
levels did not markedly change (Figure 1B, Table III in 
the Data Supplement). We found no statistically sig-
nificant linear correlations between SN levels and other 
biomarkers, or between changes in SN levels and other 
biomarkers after ventricular arrhythmia (Table IV in the 
Data Supplement). Moreover, variables associated with 
change in SN levels, as assessed by multivariable linear 
regression analysis, differed from the variables associ-
ated with change in hs-TnT and NT-proBNP levels after 
ventricular arrhythmia (Table V in the Data Supplement). 
These observations link SN expression more closely to 
cardiomyocyte Ca2+ handling and support that SN eleva-
tion may better distinguish patients at risk for arrhyth-
mia than established cardiac biomarkers, identifying 
additional myocardial pathophysiology.
SN Overexpression Reduces Arrhythmia 
in CPVT Mice
Based on the above findings in subjects with increased 
prevalence of arrhythmia, and our prior data indicat-
ing that SN can inhibit CaMKIIδ,7 we hypothesized that 
SN elevation has compensatory, antiarrhythmic actions. 
To investigate this, we used CPVT mice (RyR2-R2474S 
mutation). CPVT mice exhibited an upregulation of SgII 
at baseline (Figure 2A). SN was further overexpressed in 
3- to 5-day-old animals using a single, intrathorax injec-
tion of adeno-associated virus 9, which has strong tro-
pism for cardiac tissues.16 A scrambled construct served 
as control. Imaging and polymerase chain reaction anal-
ysis of the mCherry fusion protein documented robust 
expression of both SN and scrambled construct pep-
tides in cardiomyocytes into adulthood (Figure 2B and 
2C). During stress testing with isoproterenol, telemetric 
recordings revealed that few arrhythmias were induced 
in WT mice (Figure  2D and 2E). A statistically signifi-
cant higher number of arrhythmic events was observed 
in CPVT animals transfected with scrambled peptide, 
but not SN (Figure 2E). An arrhythmia score assigned 
based on the severity of the event observed (ventricular 
extrasystoles, bigeminy, couplets, or ventricular tachy-
cardia, described in the legend of  Figure 2F) similarly 
showed a statistically significant higher score in CPVT 
mice transfected with scrambled peptide but not SN, 
in comparison with WT controls. Of particular preva-
lence was a lower incidence of ventricular tachycardia 
in CPVT animals treated with SN, both in terms of num-
ber of events (Figure 2E) and proportion of affected ani-
mals (Figure 2G). This finding supports compensatory 
antiarrhythmic actions by SN upregulation in subjects 
with CPVT.
SN Interacts With the S-Site in the 
Catalytic Region of CaMKIIδ and Reduces 
Autophosphorylation of CaMKIIδ During 
β-Adrenergic Challenge
Based on the above findings in patients and mice at 
risk for arrhythmia, and our prior data indicating that 
SN can inhibit CaMKIIδ,7 we examined the mecha-
nism by which SN elevation protects against Ca2+- 
dependent arrhythmogenesis. To this end, we first 
aimed to identify SN binding sites on CaMKIIδ based 
on established knowledge of its domain organiza-
tion (Figure 3A). 3xFLAG-CaMKIIδ full length (T287D 
mutated, constitutive active) and deletion variants were 
designed and expressed in human embryonic kidney 
293 cells. Pull-down experiments with a biotinylated 
SN peptide revealed that all 3xFLAG-CaMKIIδ variants 
precipitated with SN, except 3xFLAG-CaMKIIδ (1–50), 
which lacks the S-site (also known as docking site A3) 
in the catalytic domain (Figure 3B, upper). This find-
ing suggests that SN binds to the S-site. Indeed, bio-
informatics revealed 2 sequence homologies between 
SN and the S-site binding region of the regulatory 
domain, which contains the autophosphorylation site 
Thr287 (Figure 3C). In line with this finding, modeling 
of SN binding to CaMKIIδ revealed 2 possible SN-S-site 
interactions, centered either at Thr163 (model 1) or 
Thr169 (model 2) in SN/SgII (Figure 3C and D, upper 
and lower, respectively). Both models contained favor-
able hydrophobic interactions (blue dashed lines) and 
hydrogen bonds (yellow dashed lines) between SN and 
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Figure 1. SN (secretoneurin) levels are increased in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT) and patients after  
out-of-hospital cardiac arrest.  
A, Circulating SN levels were higher in patients with CPVT (n=8) compared with control subjects (n=9), both at rest and after a short-term exercise test. Levels of catechol-
amines, hs-TnT (high-sensitivity troponin T), NT-proBNP (N-terminal pro-B-type natriuretic peptide), and CgA, CgB (chromogranins A and B) were unchanged. *P<0.05, 
by Mann-Whitney U test. B, Circulating SN levels were elevated after resuscitation for ventricular arrhythmia–induced cardiac arrest (n=155), when the risk of subsequent 
ventricular arrhythmias and mortality are highest, followed by a decline of circulating SN levels after 24 h when the risk is low. In contrast, hs-TnT levels did not markedly 
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over model 1, as the latter also contained an unfa-
vorable repulsive interaction between Glu160-SN/SgII 
and Glu97-CaMKIIδ (red dashed line). Model 2 was 
further supported by SN mutational analysis showing 
that biotin-SN (L170F, V173F) bound more strongly 
than SN to His-CaMKIIδ (69–282; Figure  3E). The 2 
aromatic residues (phenyl-alanines) in L170F/V173 
may enhance peptide binding to CaMKIIδ by aromatic 
Figure 2. SN (secretoneurin) overexpression attenuates in vivo arrhythmia in catecholaminergic polymorphic ventricular tachycardia (CPVT) mice.  
A, Microarray analysis revealed increased myocardial pro-SN mRNA concentrations in CPVT mice, both in animals treated with NaCl or 20 mg/kg isoproterenol 
(ISO) sulfate for 3 d via an osmotic minipump. Wild-type (WT) control vs CPVT control: false discovery rate (FDR) <0.001, fold change 1.95. WT ISO vs CPVT ISO: 
FDR <0.001, fold change 1.67. B, SN levels were further increased in newborn mouse hearts via intrathorax injection of adeno-associated virus 9. Comparison was 
made with scrambled construct (SCR). Robust ventricular expression of the constructs was observed into adulthood, as demonstrated by imaging of the mCherry 
fusion protein (co-staining of cell membranes with wheat-germ agglutinin) and (C) polymerase chain reaction analysis. *P<0.05 by 1-way ANOVA on Ranks with 
Dunn test for multiple comparisons. D, Telemetric recordings during ISO stress testing revealed frequent arrhythmias in CPVT mice expressing SCR but not SN 
peptide. E, Arrhythmia events were categorized and tallied by a blinded observer during the first 5 min of stress testing. *P<0.05 by 1-way ANOVA on Ranks with 
Dunn test for multiple comparisons. F, An arrhythmia score was assigned based on the severity of the event; ventricular extrasystole (VES)=1 point, bigeminy=2 
points, couplets=3 points, or ventricular tachycardia (VT)=4 points. *P<0.05 by 1-way ANOVA on Ranks with Dunn test for multiple comparisons. G, In comparison 
with WT mice, VT was observed in a higher proportion of CPVT mice transfected with SCR but not SN. *P<0.05 by Fisher exact test. (CPVT mice: SCR: n=9, SN: 
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Figure 3. SN (secretoneurin) interacts with the S-site in the catalytic region of CaMKIIδ (Ca2+/calmodulin-dependent protein kinase IIδ) and inhibits 
autophosphorylation of CaMKIIδ during β-adrenergic challenge.  
A, Schematic diagram of the various Flag-CaMKIIδ constructs expressed in human embryonic kidney 293 cells used to examine SN binding. B, Western blot analyses 
demonstrated co-precipitation of SN with CaMKIIδ only when the S-site was present (upper panel). Lower: Shows equal expression of all Flag-CaMKIIδ variants 
(control blot; n=2). C, Sequence alignments of SN, centered either at Thr163 or Thr169 (numbering according to SgII [secretogranin II]) to the substrate binding 
Thr287-segment in CaMKIIδ (upper schematic in lower). The S-site spans residues E97 and E140 in CaMKIIδ (E96 and E139 in CaMKIIα).18 D, Structural models 
of the 2 possible SN-S-site interactions, centered either at Thr163-SN/SgII (model 1, upper) or Thr169-SN/SgII (model 2, lower). SN is shown as a ball-and-stick 
model, with S-site residues Glu97 and Glu140 in light green; CaMKIIδ is shown in yellow. Upper: Putative favorable hydrophobic interactions between Val158- SN/
SgII and Phe99/Val103-CaMKIIδ, as well as Val167-SN/SgII and Phe174-CaMKIIδ are shown as blue dashed lines. Hydrogen bonds to SN side chains are shown in 
yellow. An unfavorable repulsive interaction between Glu160-SN/SgII and Glu97-CaMKIIδ is indicated in red. Lower: Putative favorable hydrophobic interactions 




 http://ahajournals.org by on July 22, 2019
Ottesen et al; Secretoneurin and Arrhythmia
Circ Arrhythm Electrophysiol. 2019;12:e007045. DOI: 10.1161/CIRCEP.118.007045 April 2019 8
stacking with Phe174. SN binding was greatly reduced 
when CaMKIIδ (69–282) was omitted or replaced with 
a nonrelevant protein without any S-site (negative 
controls). Thus, our data support that a region of SN 
centered around Thr169 binds within a pocket of the 
S-site of CaMKIIδ. As the CaMKIIδ-S-site is responsible 
for autophosphorylation of Thr287 in the neighboring 
CaMKIIδ molecule in the dodecamer,3 we postulated 
that SN binding to the S-site blocks autophosphory-
lation and thereby limits kinase activity. Indeed, SN 
was observed to inhibit isoproterenol-induced Thr287 
phosphorylation in Langendorff hearts perfused with 
100 nmol/L isoproterenol (Figure 3F).
SN Inhibits CaMKIIδ-Dependent 
Phosphorylation of RyR2 and Ca2+ 
Sparks
In agreement with an observed inhibition of CaMKIIδ 
activity by SN, SN treatment also reduced isopro-
terenol-induced CaMKIIδ-dependent phosphory-
lation of RyR2. Although isoproterenol perfusion 
increased phosphorylation at the known CaMKIIδ and 
PKA  (protein kinase A) regulatory sites (pSer2814-
RyR2 and pSer2808-RyR2, respectively), this effect 
was statistically only significantly reversed by SN at 
the CaMKIIδ site (Figure 4A). Consistent with inhibi-
tion of CaMKIIδ-dependent phosphorylation of RyR2, 
SN treatment (2.8 μM) tended to reduce both the 
frequency and dimensions of Ca2+sparks in isolated 
cardiomyocytes (Figure 4B). These effects were exag-
gerated in the presence of isoproterenol (Figure 4B). 
More modest effects were observed for a 1000X low-
er dose of SN (2.8 nmol/L, Figure I in the Data Supple-
ment), which is in the range of the highest circulating 
levels observed in patients with out-of-hospital car-
diac arrest (>2 nmol/L).
SN Inhibits Ca2+ Waves and DADs
In line with a reduction in RyR2 activity, SN treatment 
increased sarcoplasmic reticulum (SR) Ca2+ content at 
baseline (Figure II in the Data Supplement). SN also 
decreased the incidence of spontaneous Ca2+ waves, 
both at baseline and during β-adrenergic challenge 
(Figure 5A). In patch-clamp experiments, these effects 
were manifested as an observed reduction in DAD fre-
quency in cells paced at 1 Hz (Figure 5B). Generated 
DADs were frequently observed to trigger spontane-
ous action potentials, and SN treatment tended to 
reduce the occurrence of these events (Figure 5B).
SN Inhibits EADs and L-type Ca2+  
Current (ICaL)
Given the role of CaMKIIδ in promoting EADs, we 
examined whether SN treatment attenuated arrhyth-
mogenesis by this mechanism. In patch-clamp experi-
ments, isoproterenol markedly increased EAD gen-
eration in paced cardiomyocytes; an effect that was 
strongly inhibited by SN (Figure 5C). SN also reduced 
L-type Ca2+ current (Figure 5D), an important CaMKIIδ-
sensitive EAD trigger5,6 but did not alter kinetics of cur-
rent decay (τfast =18.4±1.4 ms, 24.1±3.2 ms in control, 
SN; P=not significant by t test). Thus, our results support 
that elevation of SN levels reduces arrhythmogenesis 
during isoproterenol stimulation by inhibiting cellular 
mechanisms underlying both EADs and DADs, suggest-
ing a compensatory role of SN in patients at high risk 
for arrhythmias.
DISCUSSION
The principal findings of this study are summarized 
in the graphic abstract. Circulating SN levels were 
increased in patients with CPVT, who exhibit pathologi-
cal cardiomyocyte Ca2+ handling. High SN levels were 
also observed in cardiac arrest patients during the early 
phase following arrhythmia when risk of a new arrhyth-
mia is high and then normalized within 24 hours. This 
temporal profile of SN levels after ventricular arrhythmia 
differed from the profile of hs-TnT and NT-proBNP, sug-
gesting that SN levels may better distinguish patients 
at risk for arrhythmia and reflect additional myocardial 
pathophysiology compared with established cardiac 
biomarkers. A compensatory role of SN upregulation 
was indicated in CPVT mice, as myocardial pro-SN syn-
thesis was increased in animals with CPVT, and adeno-
associated virus-9–induced SN overexpression reduced 
arrhythmic incidence and severity during stress testing. 
In experimental studies aimed at identifying the arrhyth-
mic implications of SN upregulation, we observed that 
SN binds to the S-site of CaMKIIδ, a well-established 
contributor to arrhythmogenesis in cardiomyocytes.1 
SN binding was found to reduce CaMKIIδ autophos-
phorylation and phosphorylation of its target proteins 
and to lower the prevalence of DADs and EADs during 
β-adrenergic stimulation. These findings indicate that 
SN upregulation offers compensatory protection against 
ventricular arrhythmia, which underlies its putative use 
as a prognostic biomarker in at-risk patients.
To be clinically relevant, novel biomarkers should 
reflect pathophysiology of relevance for morbidity and 
Figure 3 Continued. shown as blue dashed lines. Hydrogen bonds to Thr169-SN/SgII are shown in yellow. E, Using the ELISA technique, mutagenesis studies 
supported the validity of model 2, as SN binding was greatly reduced when CaMKIIδ 69–282 was omitted (SN+PBS) or replaced by a nonrelevant amino acid 
sequence. *P<0.05, examined by 1-way ANOVA with Bonferroni Multiple Comparison test. (SN+CaMKII 69–282: n=12; SN (L170F, V173F) + CaMKII 69–282: 
n=6; SN+PBS: n=6; SN+nonrelevant protein: n=6). F, SN reduced ISO-induced autophosphorylation of Thr287-CaMKIIδ in Langendorff-perfused hearts. *P<0.05, 
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mortality in cardiovascular disease. Our present data link 
SN directly to cardiomyocyte Ca2+ mishandling, which 
mechanistically supports the previously reported asso-
ciation to poor outcome in patients with myocardial dys-
function.7–10,12,19 Specifically, our earlier work identified 
SN elevation in blood samples from patients with acute 
Figure 4. SN (secretoneurin) reduces CaMKIIδ (Ca2+/calmodulin-dependent protein kinase IIδ)-dependent phosphorylation of RyR2 (ryanodine 
receptor 2) and Ca2+ sparks.  
A, Isoproterenol (ISO) stimulation of Langendorff-perfused hearts increased RyR2 phosphorylation at both CaMKII- and PKA (protein kinase A)-dependent sites 
(Serine2814 [Ser2814] and Ser2808, respectively). SN treatment inhibited phosphorylation at Ser2814 only. *P<0.05, examined by Student t test. (Control [Ctr]: 
n=5; ISO: n=4; SN+ISO: n=3). B, SN treatment of cardiomyocytes reduced the frequency and geometry of spontaneous Ca2+ sparks, particularly in the presence of 
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HF,7,11 critically ill patients with infections,9 and in patients 
with cardiovascular related-acute respiratory failure.10 
Importantly, SN levels provided additional prognostic 
information to established risk scores and biomarkers in 
these patients, whereas SN levels did not improve risk 
assessment in patients with pulmonary disease.7,10,12 The 
cardiac syndromes examined in these previous studies 
are associated with excessive β-adrenergic stimulation 
and CaMKIIδ activation. We presently show that myo-
cardial and circulating SN levels are increased also in sub-
jects with CPVT, a condition in which the mutated, leaky 
RyR2 activates CaMKIIδ, and the resulting phosphoryla-
tion of RyR2 further sensitizes the channel in a positive-
feedback loop.20,21 These effects are exaggerated during 
β-adrenergic stimulation,2 and therefore, a system that 
could counteract the detrimental effects of excessive 
Figure 5. SN (secretoneurin) inhibits 
the generation of delayed afterdepo-
larizations (DADs) and early afterdepo-
larization (EADs) during β-adrenergic 
challenge.  
A, Ca2+ waves were recorded by whole-cell 
fluorescence in cardiomyocytes after termina-
tion of 1 Hz field stimulation. Including 2.8 
µmol/L SN in the superfusate reduced Ca2+ 
wave frequency, both at baseline and during 
isoproterenol (ISO)-treatment. *P<0.05, by 
Mann-Whitney test. (Control [Ctr]: nhearts=7, 
ncells=19; SN: nhearts=6, ncells=24, ISO: nhearts=7, 
ncells=27; SN+ISO: nhearts=4, ncells=22). B, In 
concordance with attenuated wave genera-
tion, SN treatment reduced the frequency of 
DADs (arrows) observed during ISO challenge 
in patch-clamped cells paced at 1 Hz. The fre-
quency of DAD-induced spontaneous action 
potentials (APs) also tended to be reduced in 
the ISO + SN group. *P<0.05, by Mann-Whit-
ney test. (Ctr: nhearts=6, ncells=9; SN: nhearts=3, 
ncells=11; ISO: nhearts=6, ncells=10; SN + ISO: 
nhearts=3, ncells=11). C, SN treatment decreased 
the appearance of EADs (arrows) induced by 
ISO stimulation. The occurrence of sustained 
EADs lasting an entire cycle length was also 
attenuated. *P<0.05, by Mann-Whitney test. 
(Ctr: nhearts=6, ncells=9; SN: nhearts=3, ncells=11; 
ISO: nhearts=6, ncells=10; SN + ISO: nhearts=3, 
ncells=11). D, SN reduced L-type Ca
2+ current 
(ICaL), a known CaMKII (Ca
2+/calmodulin-
dependent protein kinase II)-sensitive trigger 
of EAD generation. *P<0.05 by 2-way ANOVA 
with Bonferroni test for multiple comparisons. 
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CaMKIIδ activity is expected to be protective in patients 
with CPVT. The early increment in circulating SN levels 
after ventricular arrhythmia–induced cardiac arrest also 
fits a model of SN as an endogenous CaMKIIδ inhibi-
tor as the risk of new ventricular arrhythmic events is 
highest early after hospital admission.7 In contrast to SN 
levels, which rapidly decreased after patients had been 
resuscitated for ventricular arrhythmias, NT-proBNP lev-
els increased over time, and hs-TnT levels did not mark-
edly change. Still, as dysregulated cardiomyocyte Ca2+ 
homeostasis may impact both the risk of ventricular 
arrhythmias and systolic and diastolic function, it is cur-
rently not clear whether SN assessment in HF patients 
could distinguish patients at risk of arrhythmias from 
those at risk of worsening HF with pulmonary conges-
tion. Accordingly, there is a need for additional clinical 
and experimental studies to explore this question more 
closely. We also cannot completely rule out that the dif-
ference in β-blocker use between patients with CPVT 
and control subjects may have altered SN concentra-
tions as β-blockers also influence cardiomyocyte Ca2+ 
homeostasis. However, we have previously found that 
β-blocker treatment was not associated with increased 
SN concentrations in patients with acute HF,7 and we did 
not presently find a correlation between β-blocker dose 
and SN concentration in our patients with CPVT (Table 
II in the Data Supplement). The increase in myocardial 
pro-SN synthesis in CPVT mice, which were not treated 
with β-blockers, also supports that the difference in 
medication alone cannot explain our results. Hence, we 
believe that differences in SN concentrations between 
patients with CPVT and control subjects are most likely 
rooted in the disease pathophysiology.
As SN is formed by the cleavage of SgII, elevation of 
circulating SN levels in CPVT and cardiac arrest patients 
could result from increased SgII production. Indeed, we 
observed augmented SgII production in cardiomyocytes 
from CPVT mice at baseline (Figure 2A), and we have 
previously observed increased SgII transcription in postin-
farction HF.8 Upregulation of SgII has also been shown to 
be induced in mice during hypoxia.22 Thus, SgII upregula-
tion may be a common feature of various cardiac pathol-
ogies. However, it is difficult to verify this claim in our 
present patient cohorts because we did not have access 
to myocardial biopsies and because it is mainly the SN 
cleavage product that is measured in blood (>90%).23,24 
Alternatively, processing of SgII to SN may be increased 
in the patient populations examined, paralleling our pre-
vious observations in HF, where enhanced SgII cleavage 
was attributed to upregulation of proprotein convertase 
1/3 and proprotein convertase 2.8 Finally, SN may be 
released from existing stores in cardiac cells in CPVT and 
cardiac arrest patients, or there may be leakage of SN 
into the circulation from other organs, such as the lung 
or brain, as previously suggested.19 Although the precise 
source of SN in our patient cohorts is unclear, so too is 
the initiating trigger. One possibility is that elevation of 
SN may be signaled by rising Ca2+ levels. The cytosolic 
Ca2+ concentration is high during arrhythmias and myo-
cardial injury, and high cytosolic Ca2+ concentration is a 
well-known activator of CaMKIIδ. Thus, increased SN 
levels could provide a feedback mechanism to prevent 
excessive CaMKIIδ activation.
A growing consensus linking CaMKIIδ activation to 
cardiac arrhythmia during β-adrenergic stimulation has 
indicated an involvement of both cAMP/exchange factor 
directly activated by cAMP (Epac)–dependent and cAMP-
independent signaling pathways.2 Numerous previous 
reports have linked CaMKIIδ-dependent activation of 
RyRs and L-type Ca2+ channels to generation of DADs and 
EADs and shown that CaMKIIδ inhibition protects against 
such Ca2+-dependent arrhythmogenesis.1 The present 
study is, to the best of our knowledge, the first to show 
such antiarrhythmic effects of an endogenous CaMKIIδ 
inhibitor. We have recently reported that SN is readily 
taken up into cardiomyocytes by endocytosis,7 whereas 
limited cardiomyocyte uptake of other CaMKIIδ inhibitors 
precludes their possible use in patients.1 We now pres-
ent data showing that SN binds within a pocket of the 
S-site of CaMKIIδ, with modeling predicting 2 possible 
interaction sites. Follow-up mutagenesis experiments 
specifically supported that the binding region of SN cen-
ters around Thr169. Such binding may directly interfere 
with the ability of the kinase domain to phosphorylate its 
targets, including Ser2814 on RyR2. SN blockade of the 
S-site also seems to limit autophosphorylation at Thr287 
and thereby kinase activity. It is interesting to note that 
although we previously reported that SN provides rather 
modest reduction in CaMKIIδ activity,7 our present results 
show more striking effects on CaMKIIδ phosphorylation 
targets and the incidence of Ca2+ sparks, waves, DADs, 
and EADs during isoproterenol stimulation. The reason 
for this discrepancy may be because of feed-forward 
mechanisms present in cells not accounted for in ex 
vivo assays. In cells, CaMKIIδ is stimulated by local Ca2+ 
levels. Therefore, by inhibiting CaMKIIδ and thus RyR2 
leak, SN is expected to reduce the pool of dyadic Ca2+ 
which regulates local CaMKIIδ. In electrically stimulated 
cells, inhibition of L-type Ca2+ current by SN may addi-
tionally reduce this local dyadic Ca2+ pool. Of note, pre-
vious work has linked CaMKIIδ activity to facilitation of 
Ca2+ current, manifested as a proarrhythmic slowing of 
current kinetics.25 As this phenomenon is predominantly 
present at physiological resting potentials, our present 
measurements of L-type currents using depolarized hold-
ing potentials may, in fact, underestimate the extent of 
SN-dependent CaMKIIδ inhibition.
Although CaMKIIδ-dependent activation of RyRs 
and L-type Ca2+ channels promotes the generation 
of DADs and EADs, it is important to point out that 
these effects can be codependent and that the pres-
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ping roles. For example, although CaMKIIδ-dependent 
phosphorylation of the L-type Ca2+ channel increases 
the likelihood of EADs,5,6 increased L-type current also 
loads the SR and promotes spontaneous RyR2 Ca2+ 
release (DADs).1 Similarly, although increased RyR2 
open probability promotes Ca2+ waves/DADs during 
diastole, Ca2+ release during action potential repolar-
ization can promote EADs.26 Protection against EADs 
and DADs by SN may also involve additional CaMKIIδ-
regulated proteins and include inhibition of late Na+ 
current and various K+ channels.
Although we have presently observed encouraging 
effects of SN treatment in CPVT mice, additional stud-
ies are required to assess the potential of exogenous 
SN as a therapeutic drug. It is interesting to note that 
overall Ca2+ homeostasis was not negatively affected 
by SN treatment. A baseline reduction in Ca2+ leak 
was associated with increased SR content and Ca2+ 
transient magnitude in the SN group (Figure IIA in the 
Data Supplement). Such differences were not observed 
during isoproterenol, where SR content and release 
were markedly elevated but similar in SN-treated and 
untreated cells. β-adrenergic stimulation augments 
SR function via phosphorylation of phospholamban at 
Ser16 and Thr17, which disinhibits sarcoendoplasmic 
reticulum Ca2+-ATPase. SN treatment reversed isopro-
terenol-dependent phosphorylation at the CaMKIIδ-
dependent Thr17 site (Figure IIB in the Data Supple-
ment). Thus, effects of CaMKIIδ inhibition by SN seem 
to balance reductions in SR Ca2+ leak and reuptake dur-
ing β-adrenergic challenge, resulting in maintained SR 
content and Ca2+ transients while inhibiting Ca2+ wave/
DAD generation. Patient groups such as those with 
HF might, therefore, benefit from the antiarrhythmic 
effects of SN without risk of reduced contractility.
In conclusion, our results support antiarrhythmic 
actions of the endogenous peptide SN via inhibition of 
CaMKIIδ activity, L-type Ca2+ channel opening, and the 
generation of EADs and DADs. We suggest that these 
actions underlie SN’s applicability as a biomarker and, 
with further work, that patients at risk for arrhythmia 
may potentially benefit from exogenous SN.
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